FDA Approves Leqembi: In an unprecedented move, the U.S. Food and Drug Administration (FDA) has granted traditional approval to Leqembi (lecanemab-irmb), a novel drug used to treat adult patients with Alzheimer’s Disease. This follows the successful completion of a confirmatory trial that established clinical benefits. Leqembi, which has the distinction of being the first amyloid beta-directed antibody to transition from accelerated to traditional approval, is … Continue reading FDA Approves Leqembi as Traditional Alzheimer’s Treatment